The Addition of Bevacizumab (BEV) to Temozolomide (TMZ) and Radiation Therapy (RT) in Newly Diagnosed Glioblastoma (GBM) Improves Progression-Free Survival (PFS) Without Adding to RT Toxicity

Authors :: Wolfgang Wick
Roger Henriksson
Yannick Kerloeguen
Ryo Nishikawa
O. L. Chinot
Timothy F. Cloughesy
Magalie Hilton
Frank Saran
W. Mason
Source :: International Journal of Radiation Oncology*Biology*Physics. 87:S16
Publication Year :: 2013
Publisher :: Elsevier BV, 2013.
Abstract: The Addition of Bevacizumab (BEV) to Temozolomide (TMZ) and Radiation Therapy (RT) in Newly Diagnosed Glioblastoma (GBM) Improves Progression-Free Survival (PFS) Without Adding to RT Toxicity

Tools